M3 Wealth Management LLC acquired a new position in Astrazeneca Plc (NYSE:AZN – Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 3,842 shares of the company’s stock, valued at approximately $674,000.
Several other institutional investors also recently modified their holdings of AZN. Bank of Montreal Can increased its position in shares of Astrazeneca by 344.6% in the third quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock worth $266,841,000 after purchasing an additional 2,695,793 shares during the last quarter. Holocene Advisors LP increased its position in shares of Astrazeneca by 41.8% in the third quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock worth $470,232,000 after purchasing an additional 1,807,565 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich increased its position in shares of Astrazeneca by 11,190.9% in the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,806,877 shares of the company’s stock worth $317,107,000 after purchasing an additional 1,790,874 shares during the last quarter. Raymond James Financial Inc. grew its position in Astrazeneca by 64.8% during the second quarter. Raymond James Financial Inc. now owns 3,783,251 shares of the company’s stock valued at $264,373,000 after acquiring an additional 1,487,662 shares during the last quarter. Finally, Bank of America Corp DE grew its position in Astrazeneca by 4.7% during the third quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock valued at $2,503,614,000 after acquiring an additional 1,461,786 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of research analysts have commented on the stock. Sanford C. Bernstein reiterated a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. DZ Bank upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a research report on Thursday, May 21st. Jefferies Financial Group reiterated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, May 13th. Finally, TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $205.33.
Astrazeneca Stock Up 0.0%
Shares of NYSE AZN opened at $187.10 on Wednesday. Astrazeneca Plc has a one year low of $137.23 and a one year high of $212.71. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. The firm’s 50 day simple moving average is $191.50 and its two-hundred day simple moving average is $183.36. The stock has a market capitalization of $290.18 billion, a P/E ratio of 28.09, a PEG ratio of 1.59 and a beta of 0.26.
Astrazeneca (NYSE:AZN – Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. The firm had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. As a group, analysts expect that Astrazeneca Plc will post 9.62 EPS for the current fiscal year.
About Astrazeneca
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Further Reading
- Five stocks we like better than Astrazeneca
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
